The therapeutic potential of targeting c-KIT in this subgroup of melanomas was validated by two clinical studies where patients with activating mutations in c-KIT showed significant responses to the c-KIT inhibitor imatinib (14,15); however, overall clinical responses to this inhibitor are less pronounced than to BRAF inhibitors. Here, BRAF is linked to melanoma.